



# FINANCIAL TEAR SHEET

## Corporate Profile


Jounce Therapeutics is a clinical stage immuno-oncology company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce integrates translational science insights, including identification of related biomarkers designed to match the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as knowledge acquired from Jounce’s Translational Science Platform, to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more long-lasting responses to treatment.

## Stock Information

### JNCE (COMMON STOCK)

<b>Exchange</b>	NASDAQ GS (US Dollar)
<b>Price</b>	\$13.45
<b>Change (%)</b>	▲ 0.05 (0.37%)
<b>Volume</b>	93,537
<b>52 Week Low</b>	\$12.88
<b>Market Cap</b>	\$431,088,184
<b>Rolling EPS</b>	6.07
<b>PE Ratio</b>	2.206
<b>Shares Outstanding</b>	32,170,760

Data as of 07/21/17 12:44 p.m. ET



## Recent Headlines & Events

06/05/17 - 9:00 a.m.

Jounce Therapeutics Presents Phase 1 Data from ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors at 2017 ASCO Annual Meeting

05/17/17 - 5:00 p.m.

Jounce Therapeutics to Present Phase 1 Data from JTX-2011 ICONIC Trial at 2017 American Society of Clinical Oncology Annual Meeting

05/09/17 - 8:01 a.m.

Jounce Therapeutics Reports First Quarter 2017 Financial Results

There are currently no events scheduled.

## SEC Filings

FILING DATE	FORM
05/23/17	8-K
05/09/17	10-Q
05/09/17	8-K
04/20/17	8-K

Data provided by NASDAQ. Stock information is delayed a minimum of 15 minutes.